APOB and type 2 diabetes mellitus: Alirocumab significantly reduced non-HDL-C, LDL-C, ApoB, and LDL-PN from baseline to week 24 versus controls among individuals with T2DM and ASCVD in the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies (Fig. 1).